Standard lipid testing is a well-established way to predict and manage risk in cardiovascular disease (CVD).
However, despite standard lipid testing’s generally decent track record, a large portion of cardiovascular disease cases remain unaddressed.
To counter the limitations of standard testing, some practitioners prefer advanced lipoprotein analysis: a more intuitive way of predicting risk and individualising therapy for CVD prevention. It’s also able to identify at-risk patients even with lower cholesterol levels.
For people with diabetes, advanced lipid analysis makes a lot of sense.
- Heart attack and stroke are the most common causes of mortality in diabetes (In fact, people with diabetes are 48% more likely to suffer a heart attack than the general population, according to one of the largest research projects into the health and care of people with the disease.)
- A landmark trial called CARDS showed that people with diabetes prescribed statins had fewer cardiovascular events than those who did not
- The use of statins in diabetes is now routine, but we’re not sure if enough is being done for high-risk patients
- Unless you do specific tests, there’s no simple way of finding out who has high risk of an early heart attack
If you’d like to talk further about the benefits of advanced lipiprotein analysis, get in touch with one of our consultants today.